Results 1 to 3 of 3

Thread: Lupin Limited (NSE:LUPIN) (BSE:500257)

  1. #1
    Super Moderator
    Join Date
    Apr 2015
    Posts
    2,383

    Lupin Limited (NSE:LUPIN) (BSE:500257)

    Lupin limited is an India-based transnational pharmaceutical Company, producing a wide range of generic and branded formulations. The Company has market share in key markets in the cardiovascular (prils and statins), diabetology, asthma, pediatrics, CNS, GI, anti-infective and NSAIDs therapy segments, Anti-TB and, cephalosporins segments. The Company’s key divisions in India are Pinnacle Cardiology, Lupin metabolics, Lupin blue eyes, Lupin CVN, Lupin diabetes care, respira, endeavour, Lupin Mindvision, Lupin Ikonic, Lupin Maxter, anti-tuberculosis, anti-biotics, gynaecology, orthopaedic and dermatology division. The Company is a key player in India’s respiratory (anti-asthma) segment, cardiovascular segment and the diabetes segment.

    Official website: www.lupinworld.com

  2. #2
    Super Moderator
    Join Date
    Apr 2015
    Posts
    2,383
    For 4QFY2015, Lupin posted numbers below our expectations. On the top-line front, Lupin posted a flat growth of 0.1% yoy to Rs3,054cr (V/s Rs3,515cr expected). The key geographies - US, Europe, India and Japan posting a dip of 6%, a growth of 9%, a growth of 15% and a dip of 9%, respectively. On the operating front, the gross margins expanded by 79bp yoy; inspite of the same, the OPM dipped by 142bp yoy to 25.1% (V/s an expected 26.3%). The PAT came in at Rs547cr (V/s Rs626cr expected), posting a yoy de-growth of 1.1%. We maintain our Neutral rating on the stock. Below expectation numbers: On the top-line front, Lupin posted a flat growth of 0.1% yoy to Rs3,054cr (V/s Rs3,515cr expected). The key geographies - US, Europe, India and Japan posting a dip of 6%, a growth of 9%, a growth of 15% and a dip of 9%, respectively. Other markets like South Africa and ROW posted a 15% growth and a dip of 3%, respectively. On the operating front, the gross margins expanded by 79bp yoy; inspite of of the same, the OPM dipped by 142bp yoy to 25.1% (V/s an expected 26.3%). The main reason for variance is lower-than-expected sales. Also, the employee cost and R&D expenditure rose by 23.8% and 26.1% yoy respectively. R&D expenditure during the quarter was 10.1% of sales V/s 8.0% of sales in 4QFY2014. Thus, the PAT came in at Rs547cr (V/s Rs626cr expected), posting a yoy de-growth of 1.1%. Outlook and valuation: We expect Lupin to post a CAGR of 17.0% in net sales to Rs17,244cr and earnings to report a 15.3% CAGR to Rs71.1/share over FY2015–17E. Currently, the stock is trading at 27.2x and 23.8x its FY2016E and FY2017E earnings, respectively. We remain Neutral on the stock.

    Source http://www.angelbroking.com
    Attached Files Attached Files
    Last edited by SMR; 05-15-2015 at 01:20 PM.

  3. #3
    Super Moderator
    Join Date
    Apr 2015
    Posts
    2,383
    Lupin announced lower-than-expected numbers for 1QFY2016. Its sales for the quarter dipped by 6.4% yoy to Rs3,074cr V/s an expected Rs3,600cr. Overall formulations posted a sales dip of 8.0% yoy to Rs2,748.6cr and APIs posted an 11% yoy growth to Rs325.7cr. On the operating front, the gross margin came in at 68.0% V/s an expected 65.5% and V/s 67.9% in the corresponding previous year period. EBITDA margin came in at 24.2% V/s an expected 27.0% and V/s 32.2% in 1QFY2015. Consequently, the PAT came in at Rs525.5cr V/s an expected Rs749cr and V/s Rs624cr in 1QFY2015, ie a decline of 15.8% yoy. We are Neutral on the stock, given the valuations. Below expectation numbers: Lupin’s sales for the quarter dipped by 6.4% yoy to Rs3,074cr V/s an expected Rs3,600cr. Overall formulations posted a sales dip of 8.0% yoy to Rs2,748.6cr and APIs posted an 11% yoy growth to Rs325.7cr. Formulation sales dipped as US posted a decline of 26% yoy to Rs1,109.6cr, owing to the base impact and on account of a few launches during the quarter. On the operating front, the gross margin came in at 68.0% V/s an expected 65.5% and V/s 67.9% in the corresponding previous year period. EBITDA margin came in at 24.2% V/s an expected 27.0% and V/s 32.2% in 1QFY2015. The decline in EBITDA margin is mainly owing to lower sales and higher R&D expenditure. During the quarter, R&D expenditure as a percentage of sales rose to 10.2% V/s 7.4% in 1QFY2015. Consequently, the PAT came in at RS525.5cr V/s an expected Rs749cr and V/s Rs624cr in 1QFY2015, ie a yoy de-growth of 15.8%. Outlook and valuation: We expect Lupin to post a CAGR of 9.5% in net sales to Rs15,110cr and earnings to report a 9.7% CAGR to Rs64.3/share over FY2015–17E. Currently, the stock is trading at 32.1x and 25.2 its FY2016E and FY2017E earnings, respectively. We remain Neutral on the stock.

    Source: http://www.angelbroking.com/
    Attached Files Attached Files

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  
About us
StockMarketsReview.com provides news coverage, analysis and researches for world stock markets, commodities and currencies. We publish articles provided by experts of leading brokerage and investment companies. At our website investors can find daily, weekly and monthly reports, news, recommendations on the IPOs and fundamental analysis for stocks which are currently traded at the stock exchange.